We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SB-525

News List

Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 americanpharmaceuticalreview
December 24, 2019
Sangamo Therapeutics announced the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND).
Sangamo announces promising early results for haemophilia A gene therapy pharmaceutical-technology
April 23, 2019
Sangamo announces promising early results for haemophilia A gene therapy.
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy americanpharmaceuticalreview
April 11, 2019
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy.
Sangamo Announces Positive Preliminary Data from SB-525 Gene Therapy americanpharmaceuticalreview
August 10, 2018
Sangamo Therapeutics announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (Alta study).
Sangamo, Pfizer Announce First Patient Receives SB-525 Treatment in Clinical Trial expressbpd
August 28, 2017
Sangamo Therapeutics and Pfizer announced the first patient received treatment in the Phase 1/2 clinical trial (Alta trial) evaluating SB-525, an investigational gene therapy for patients with Hemophilia A, a rare genetic blood disorder.